Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

57.48
-0.6300-1.08%
Post-market: 57.900.4200+0.73%19:57 EDT
Volume:65.85M
Turnover:3.78B
Market Cap:117.02B
PE:16.61
High:58.55
Open:58.26
Low:56.91
Close:58.11
52wk High:62.89
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:5.73
T/O Rate:3.24%
Dividend:2.49
Dividend Rate:4.33%
EPS(TTM):3.46
EPS(LYR):3.46
ROE:40.44%
ROA:10.29%
PB:6.33
PE(LYR):16.61

Loading ...

Prothena partners present prasinezumab and BMS-986446 clinical study updates at AD/PD 2026

Reuters
·
Yesterday

Bristol Myers announces expanded approvals for Opdivo in U.S., EU,

TIPRANKS
·
Mar 21

BRIEF-FDA Approves Nivolumab With Chemotherapy For Previously Untreated Hodgkin Lymphoma

Reuters
·
Mar 21

Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

Benzinga
·
Mar 21

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma

Reuters
·
Mar 21

FDA: Granted Traditional Approval to Nivolumab for Adults With Relapsed or Refractory Chl After Autologous Hsct & Brentuximab Vedotin

THOMSON REUTERS
·
Mar 21

Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth

Simply Wall St.
·
Mar 20

Bristol Myers Squibb Co. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Mar 20

Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Mar 19

Bristol-Myers Squibb to report first-quarter 2026 results

Reuters
·
Mar 19

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

THOMSON REUTERS
·
Mar 19

Evotec to receive USD 10 million milestone as BMS starts Phase 1 study of BMS-986506

Reuters
·
Mar 19

How Mezigdomide Trial Progress And Sotyktu Expansion At Bristol Myers Squibb (BMY) Has Changed Its Investment Story

Simply Wall St.
·
Mar 19

Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study

TIPRANKS
·
Mar 18

Bristol-Myers Squibb Is Maintained at Hold by HSBC

Dow Jones
·
Mar 18

Opdualag’s NHS Scotland Debut Adds New Layer To Bristol-Myers Squibb Story

Simply Wall St.
·
Mar 17

Jefferies Adjusts Price Target on Bristol-Myers Squibb to $70 From $68, Maintains Buy Rating

MT Newswires Live
·
Mar 17

Bristol-Myers Squibb Co : Jefferies Raises Target Price to $70 From $68

THOMSON REUTERS
·
Mar 17

U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson

Reuters
·
Mar 17

Covid Vaccine Maker BioNTech Offers Cheap Biotech Play Given Huge Cash Reserves -- Barrons.com

Dow Jones
·
Mar 17